← Back to Screener
Biodesix, Inc. Common Stock (BDSX)
Price$13.31
Favorite Metrics
Price vs S&P 500 (26W)59.37%
Price vs S&P 500 (4W)-27.14%
Market Capitalization$124.81M
All Metrics
Book Value / Share (Quarterly)$0.16
P/TBV (Annual)14.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)32.31%
Cash Flow / Share (Quarterly)$-2.87
Price vs S&P 500 (YTD)83.53%
Gross Margin (TTM)81.11%
Net Profit Margin (TTM)-39.85%
EPS (TTM)$-4.73
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-4.73
Revenue Growth (5Y)14.20%
EPS (Annual)$-4.67
ROI (Annual)-74.92%
Gross Margin (Annual)81.11%
Net Profit Margin (5Y Avg)-91.35%
Cash / Share (Quarterly)$2.30
Revenue Growth QoQ (YoY)40.76%
ROA (Last FY)-40.31%
Revenue Growth TTM (YoY)24.08%
EBITD / Share (TTM)$-2.90
ROE (5Y Avg)-391.42%
Operating Margin (TTM)-31.50%
Cash Flow / Share (Annual)$-2.87
P/B Ratio109.67x
P/B Ratio (Quarterly)36.35x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.73x
Net Interest Coverage (TTM)-3.57x
ROA (TTM)-40.28%
EPS Incl Extra (Annual)$-4.67
Current Ratio (Annual)1.86x
Quick Ratio (Quarterly)1.86x
3-Month Avg Trading Volume1.02M
52-Week Price Return4.63%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.78
P/S Ratio (Annual)1.41x
Asset Turnover (Annual)1.01x
52-Week High$20.21
Operating Margin (5Y Avg)-77.20%
EPS Excl Extra (Annual)$-4.67
CapEx CAGR (5Y)-28.65%
26-Week Price Return63.35%
Quick Ratio (Annual)1.86x
13-Week Price Return56.68%
Total Debt / Equity (Annual)1.75x
Current Ratio (Quarterly)1.86x
Enterprise Value$153.271
Revenue / Share Growth (5Y)46.86%
Asset Turnover (TTM)1.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-39.85%
Cash / Share (Annual)$2.30
3-Month Return Std Dev144.97%
Gross Margin (5Y Avg)67.95%
Net Income / Employee (TTM)$-0
ROE (Last FY)-205.65%
Net Interest Coverage (Annual)-3.57x
EPS Basic Excl Extra (Annual)$-4.67
Receivables Turnover (TTM)10.03x
Total Debt / Equity (Quarterly)41.12x
EPS Incl Extra (TTM)$-4.73
Receivables Turnover (Annual)10.03x
ROI (TTM)-75.34%
P/S Ratio (TTM)1.41x
Pretax Margin (5Y Avg)-91.35%
Revenue / Share (Annual)$11.72
Tangible BV / Share (Annual)$2.06
Price vs S&P 500 (52W)-25.20%
Year-to-Date Return86.18%
5-Day Price Return-4.96%
EPS Normalized (Annual)$-4.67
ROA (5Y Avg)-52.85%
Net Profit Margin (Annual)-39.85%
Month-to-Date Return-12.69%
Cash Flow / Share (TTM)$-0.82
EBITD / Share (Annual)$-2.96
Operating Margin (Annual)-31.50%
LT Debt / Equity (Annual)1.74x
ROI (5Y Avg)-107.95%
LT Debt / Equity (Quarterly)41.11x
EPS Basic Excl Extra (TTM)$-4.73
P/TBV (Quarterly)16.06x
P/B Ratio (Annual)10.66x
Pretax Margin (TTM)-39.85%
Book Value / Share (Annual)$2.87
Price vs S&P 500 (13W)56.00%
Beta0.58x
Revenue / Share (TTM)$10.97
ROE (TTM)-266.80%
52-Week Low$3.44
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.18
4.18
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
BDSXBiodesix, Inc. Common Stock | — | 24.08% | -31.50% | -266.80% | $13.31 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
About
Biodesix is a lung-focused diagnostic company that provides blood-based testing services for lung cancer and COVID-19. The company generates revenue through two primary channels: direct diagnostic testing services and partnerships with biopharmaceutical companies for clinical trial diagnostics and companion diagnostic development. This dual-revenue model positions Biodesix at the intersection of clinical diagnostics and drug development, creating diverse market opportunities.